Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.88 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.88 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
| ▸ | OGA | O60502 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401416 | 1.00 | CHRNB2 (0.88) | CHRNB2CHRNA4ADRB1HTR3EHTR3B | |
| SCHEMBL5230743 | 0.94 | CHRNB2 (1.00) | CHRNB2CHRNA4ADRB1HTR3EHTR3B | |
| Trifluoroacetic Acid SCHEMBL26093287 | 0.87 | CHRNB2 (0.68) | CHRNB2CHRNA4ADRB1HTR3EHTR3B | |
| Trifluoroacetic Acid SCHEMBL2119009 | 0.87 | CHRNB2 (0.68) | CHRNB2CHRNA4ADRB1HTR3EHTR3B | |
| SCHEMBL5312452 | 0.83 | CHRNB2 (0.72) | CHRNB2CHRNA4CHRNB4CHRNA3OGA | |
| SCHEMBL3104376 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA4ADRB1HTR3EHTR3B | |
| SCHEMBL9393877 | 0.81 | CHRNB2 (0.79) | CHRNB2CHRNA4HTR3ACHRNB4CHRNA3 | |
| SCHEMBL6884588 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA4HTR3ACHRNB4CHRNA3 | |
| SCHEMBL3104417 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4ADRB1HTR3EHTR3B | |
| SCHEMBL24921493 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | Neumora Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
| WO-2019050988-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | BLACKTHORN THERAPEUTICS, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| EP-3243816-A1 | PROCESS FOR PREPARING A SUBSTITUTED AROMATIC OR HETEROAROMATIC HYDROCARBON AND ITS USE | Studiengesellschaft Kohle mbH (DE) | 2017-11-15 | — | — | EP | disclosed |
| EP-3243816-A1 | PROCESS FOR PREPARING A SUBSTITUTED AROMATIC OR HETEROAROMATIC HYDROCARBON AND ITS USE | Studiengesellschaft Kohle mbH (DE) | 2017-11-15 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
| EP-2443091-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2013-04-03 | — | — | EP | disclosed |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-19 | — | — | US | disclosed |
| WO-2010146083-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-12-23 | — | — | WO | disclosed |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| EP-2121633-A2 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099210-A2 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-5650411-A | BACTERICIDES FOR HELICOBACTER DISEASES AND BACTERIA RESISTANCE | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-07-22 | — | — | US | disclosed |
| EP-0684821-A1 | SUBSTITUTED AZOLONE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994018978-A1 | SUBSTITUTED AZOLONE DERIVATIVES FOR TREATING DISEASES CAUSED BY HELICOBACTER | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334927-A1 | Nitroimidazole Compound, Preparation Method Therefor And Use Thereof In Drug Manufacturing | NISCH, CYP51A1, CYP4F11 | CHRNB2 4757/4885CHRNA4 4716/4885ADRB1 912/4885 |
| US-20100204230-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF AD AND RELATED CONDITIONS | PSEN1, PSEN2, APP | CHRNB2 68/4885CHRNA4 211/4885ADRB1 70/4885 |
| US-20190169202-A1 | VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | AVPR1A, AVPR2, AVPR1B | CHRNB2 1338/4885CHRNA4 1119/4885ADRB1 55/4885 |
| US-20120094981-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ABCB11, ACHE, CMA1 | CHRNB2 4090/4885CHRNA4 3606/4885ADRB1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.